Biomarin Pharmaceutical Inc
SWB:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biomarin Pharmaceutical Inc
SWB:BM8
|
US |
|
Monroe Capital Corp
F:6JT
|
US |
|
Old Second Bancorp Inc
NASDAQ:OSBC
|
US |
|
Kinovo PLC
OTC:BILBF
|
UK |
|
MTN Group Ltd
F:LL6
|
ZA |
|
U
|
UBS Group AG
BMV:UBSN
|
CH |
|
P
|
PagerDuty Inc
SWB:2TY
|
US |
|
Assa Abloy AB
F:ALZC
|
SE |
|
C
|
Coca-Cola Co
BMV:KO
|
US |
|
Systemair AB
LSE:0HDK
|
SE |
|
Kuaishou Technology
HKEX:1024
|
CN |
|
G
|
G-III Apparel Group Ltd
XBER:GI4
|
US |
|
Ecovyst Inc
F:PQGA
|
US |
Wall St Price Targets
BM8 Price Targets Summary
Biomarin Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for BM8 is 77.16 EUR with a low forecast of 46.74 EUR and a high forecast of 106.03 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BM8's stock price target?
Price Target
77.16
EUR
According to Wall Street analysts, the average 1-year price target for BM8 is 77.16 EUR with a low forecast of 46.74 EUR and a high forecast of 106.03 EUR.
What is the Revenue forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 8 years is 14%.
What is the Net Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
27%
The compound annual growth rate for Net Income over the next 8 years is 27%.
